Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2927 effects on refractoriness in atrial flutter
NCT01396226Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2011
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of AZD2927 in atrial flutter (AFL), sponsored by AstraZeneca. Started Sep 2011; status: completed.
02
Drugs
AZD2927
03
Conditions
atrial flutter (AFL)
Beyond the preview
Go deeper on NCT01396226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01396226.